Delage W.,PVI Inc |
Grenier M.,PVI Inc
EVS 2016 - 29th International Electric Vehicle Symposium | Year: 2016
Based on 25 years of experience in full electric vehicles (bus & trucks) PVI - Power Vehicle Innovation - designed Watt System. WATT system allows an automatic charge at every bus stop in only 10 seconds! The original idea was patented in 2009 in order to build a full electric solution with similar performance as a diesel bus without any heavy roadworks. WATT system is now a revolution because it is the solution for a bus with an unlimited range. And it is already in operation: Nice airport (France) has entered into the future with PVI since February 2015.
News Article | May 9, 2017
REDWOOD CITY, Calif.--(BUSINESS WIRE)--SentreHEART, Inc., the manufacturer of the LARIAT+® Suture Delivery Device and the new LARIAT-RS™ will be participating in the 2017 Heart Rhythm Scientific Sessions (HR 2017) being held in Chicago, Illinois May 10-13th. The meeting’s agenda will include several sessions dedicated to exploring device-based options for Left Atrial Appendage (LAA) closure in patients diagnosed with atrial fibrillation (AFib). Physician thought leaders in this field will be relating their experience and presenting data, which will include transpericardial LAA closure with the LARIAT in multiple AFib patient populations. Included at the HRS meeting is a dedicated Industry Expert Presentation, sponsored by SentreHEART, in Rhythm Theatre II on Thursday, May 11th highlighting the aMAZE Trial. Studies have demonstrated the LARIAT not only closes the LAA mechanically1 but may also isolate electrical activity within the LAA2. With a commitment to clinical evidence development, SentreHEART is presently sponsoring the FDA-approved, prospective, multi-center, randomized controlled trial known as the aMAZE Trial. The trial, unique in its superiority design, targets the most challenging AFib population of persistent and long-standing persistent AFib patients, is intended to demonstrate a LARIAT procedure for LAA closure, plus a subsequent PVI ablation will lead to a reduced incidence of recurrent AFib compared to PVI alone; with a high safety profile. Attendees of the HR 2017 who are interested in learning more about the aMAZE Trial may attend the Industry Expert Presentation (Thursday, May 11th Rhythm Theatre II) or visit SentreHEART’s aMAZE Trial booth #1635 in the Exhibit Hall throughout the meeting. SentreHEART will also be highlighting the introduction of the LARIAT-RS, the fourth generation of LARIAT Suture Delivery Devices. The LARIAT-RS continues to improve upon the LARIAT+ device design featuring the complete snare retraction post-suture deployment and tightening, which enhances anatomic compatibility and ease of use during LARIAT procedures. For more information, visit SentreHEART booth #1635 at HR 2017 or learn more at www.sentreheart.com. SentreHEART is a privately owned medical device company based in Redwood City, CA. Founded in 2005, SentreHEART has developed innovative technology for remote delivery of suture for closure of anatomic structures including the left atrial appendage. SentreHEART is the only company that offers both percutaneous and surgical options for immediate and complete LAA closure without the need for an implant. aMAZE is an FDA-approved Trial – U.S. FDA IDE# G150107 1 Bartus K, et al. Percutaneous Left Atrial Appendage Suture Ligation Using the LARIAT Device in Patients with Atrial Fibrillation. J Am Coll Cardiol 2013 Jul 9;62(2):108-18 2 Han FT, et al. The Effects of LAA Ligation on Electrical Activity. Heart Rhythm. 2014 May; 11(5):864-70
News Article | May 12, 2017
Multicenter study shows AF ablation is safe and just as effective in patients with CHD compared to those with normal hearts PHILADELPHIA--Congenital heart disease (CHD) includes a range of defects that occur in the heart which patients are born with, such as a hole in the heart's wall, a leaky valve or even an inversion in the heart's orientation. CHD was once a severe condition often resulting in early death, but now, more and more CHD patients are living long and healthy lives. Therefore, as this population grows, so does the number of patients who are treated for other complications of their disease, such as early onset atrial fibrillation (AF), a quivering or irregular heartbeat that can lead to blood clots, stroke, heart failure and other complications. AF is often treated with a catheter ablation, a minimally invasive procedure in which the areas of the heart causing the irregularity are cauterized, but until now, there was limited data to support the safety and efficacy of treating CHD patients with an AF ablation. In a new study presented today at the Heart Rhythm Society's 38th Annual Scientific Session in Chicago, researchers from the Perelman School of Medicine at the University of Pennsylvania have found that CHD patients--even with complex defects--can safely undergo ablation for AF, with similar success rates as patients with normal hearts. "Treatment for atrial fibrillation is critical, whether the patient has a normal heart or whether they have complex congenital heart disease," said the study's presenter Jackson J. Liang, DO, a third-year cardiovascular disease fellow in the Perelman School of Medicine at the University of Pennsylvania. "In fact, atrial fibrillation can be especially detrimental in patients with complex congenital heart disease since they may be more reliant on the "atrial kick" provided during sinus rhythm. Unfortunately for some CHD patients, AF ablation may be more challenging due to the presence of complex anatomy, and the optimal ablation strategy for these patients remains to be defined." In this multicenter study, researchers performed a retrospective analysis of 69 CHD patients who underwent AF ablation, by collecting data from Penn, University of Colorado, University of California San Francisco, and Texas Cardiac Arrhythmia Institute at St. David's Medical Center. Researchers looked at those who underwent AF ablation for paroxysmal (intermittent) or persistent AF between 2008 and 2016. They identified the type of CHD, and tracked the ablation strategy - pulmonary vein isolation (PVI), PVI with additional ablation, or non-PV ablation only. "Some physicians may not be aware that catheter ablation can be performed to treat atrial fibrillation in patients with congenital heart disease, and instead they may prescribe anti-arrhythmic medications," said David Frankel, MD, an assistant professor of Cardiovascular Medicine at Penn. "We hope this study will increase awareness of catheter ablation as a viable treatment option for atrial fibrillation in these patients." Of the 69 patients, 34 had paroxysmal AF and 25 had complex CHD. The team defined complete success as freedom from recurrent AF for one year off antiarrhythmic medications, and partial success as freedom from AF recurrences for one year on previously ineffective anti-arrhythmic medications. At one year, researchers concluded that 53 percent of the patients had complete success with an additional 13 percent experiencing partial success. 92 percent of patients underwent a PVI approach, while seven percent had a non-PVI ablation alone. "We also found that 12 patients needed a repeat ablation within the first year, but most notably, there were no major procedural complications identified and only five minor complications, which is on par with rates in non-CHD patients," said Liang. "While PVI should remain the cornerstone of ablation, an individualized approach utilizing pre-procedural imaging to help to define the anatomy is necessary to improve outcomes in patients with CHD." Researchers conclude that AF ablation in this complex population was safe and effective, with similar outcomes to those seen in non-CHD patients, despite anatomical differences. However, they noted that more research is needed to further define the challenges and optimal ablation strategies in CHD patients. Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise. The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year. The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine. Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.
News Article | May 18, 2017
Pro-vegetarian diets (with a higher consumption of plant-based foods compared to animal-based foods) could provide substantial protection against obesity, according to new research presented at this year's European Congress on Obesity (ECO) in Porto, Portugal (17-20 May). This observational study found that people who ate a high pro-vegetarian diet -- rich in food coming from plant sources like vegetables, fruit, and grains -- cut their risk of developing obesity by almost half compared to those who were least pro-vegetarian -- with a dietary pattern rich in animal food like meat, and animal fats. Current evidence suggests that such a pro-vegetarian diet has a protective role in cardiovascular disease and diabetes, but little is known about its role on the risk of developing obesity in healthy populations. The study was carried by University of Navarra student Julen Sanz under the supervision of Dr. Alfredo Gea and Professor Maira Bes-Rastrollo from the University of Navarra, and CIBERobn (Carlos III Institute of Health), Spain. They examined the association between varying degrees of pro-vegetarian (plant-based) diet and the incidence of obesity (body mass index; BMI >30) in over 16,000 healthy, non-obese adults from the SUN Cohort (Seguimiento Universidad de Navarra) -- a study tracking the health of Spanish graduates since 1999. Participants completed detailed food questionnaires at the start of the study, and researchers used a pro-vegetarian diet index (PVI) to score each participant on the types of food they ate. Points were given for eating seven plant food groups -- vegetables, fruits, grains, nuts, olive oil, legumes (such as peas, beans, and lentils) and potatoes. Points were subtracted for five animal groups -- animal fats, dairy, eggs, fish and other seafood, and meat. Based on their scores, participants were categorised into five groups from the 20% with the least pro-vegetarian diet (quintile 1) to the 20% with the most (quintile 5), and followed for an average of 10 years. During follow-up, 584 participants became obese. The researchers found that participants who closely followed a pro-vegetarian diet were less likely to become obese. Modelling showed that compared to the least-vegetarian participants (quintile 1), the most vegetarian (quintile 5) had a 43% reduced risk of developing obesity. For quintiles 2, 3 and 4, the reduced risk of obesity was 6%, 15% and 17%, respectively, versus quintile 1. The results held true irrespective of other influential factors including sex, age, alcohol intake, BMI, family history of obesity, snacking between meals, smoking, sleep duration, and physical activity. The authors acknowledge that their findings show observational differences rather than evidence of cause and effect. They conclude: "Our study suggests that plant-based diets are associated with substantially lower risk of developing obesity. This supports current recommendations to shift to diets rich in plant foods, with lower intake of animal foods."
News Article | May 15, 2017
The study showed the RF balloon catheter could deliver directionally-tailored energy using multiple electrodes for efficient acute PVI in patients with paroxysmal atrial fibrillation – the heart rhythm disorder impacting the quality of life for over 3 million Americans and over 30 million people worldwide. "Existing balloon catheters are limited in a number of ways, the most significant limitation being a single ablative element that delivers identical amounts of energy along the full pulmonary vein ostium circumference," said Dr. Vivek Y. Reddy, director of Cardiac Arrhythmia Services for the Mount Sinai Hospital and the Mount Sinai Health System and study investigator. "This can lead to over-ablation of thin tissue, under-ablation of thick tissue, and unnecessary complications. The investigational RF balloon is designed to both optimize safety and efficacy and reduce procedure time." Data from the RADIANCE study was presented for the first time during a late-breaking clinical trial session at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions in Chicago. "Alarmingly, Afib increases a patient's risk of stroke by five times, but millions of patients go untreated year after year," said Shlomi Nachman, Company Group Chairman of Cardiovascular and Specialty Solutions at Johnson & Johnson. "This latest innovation comes from our obsession with solving the everyday challenges our customers face, so more patients can be treated. We're thrilled with the results from this first-in-human study and will continue studying the RF balloon catheter's safety and efficacy." Paroxysmal atrial fibrillation patients were treated with an investigational Biosense Webster, Inc. RF balloon catheter with 10 irrigated, flexible gold surface electrodes intended to independently deliver varying amount of power. Patients underwent pulmonary vein isolation where RF energy was delivered simultaneously from all electrodes – up to 30 seconds posteriorly and 60 seconds anteriorly. The primary endpoint was the incidence of primary procedure-related adverse events occurring within seven days of the procedure. Of note, any pulmonary vein stenosis, unresolved diaphragmatic paralysis or atrio-esophageal fistula that occurred also were analyzed as primary adverse events regardless of timing. Secondary endpoints included serious adverse events occurring over the course of the study and the effectiveness of electrical pulmonary vein isolation despite provocative pharmacological challenge. Results showed the RF balloon catheter was able to achieve electrical isolation of all pulmonary veins with a high rate of first-pass isolation and low evidence of latent pulmonary vein re-conduction. The procedural performance with the device was favorable, with 100 percent of the treated pulmonary veins electrically isolated without the need for a focal ablation catheter. About Biosense Webster, Inc. Biosense Webster, Inc., part of Johnson & Johnson Medical Devices Companies, is the global leader in the science of diagnosing and treating heart rhythm disorders. The company partners with clinicians to develop innovative technologies that improve the quality of care for arrhythmia patients worldwide. More information can be found at www.biosensewebster.com. *The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson's Medical Devices segment. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/first-in-human-study-shows-investigational-multi-electrode-radiofrequency-balloon-catheter-is-efficient-for-acute-pulmonary-vein-isolation-300457114.html
News Article | May 24, 2017
LONDON, UK / ACCESSWIRE / May 24, 2017 / Active Wall St. announces its dividend coverage for Johnson & Johnson (NYSE: JNJ). Shares of Johnson & Johnson will begin trading ex-dividend on May 25, 2017. In order to qualify for a dividend check, investors must own the stock on or before May 24, which is the last day the Company's management will finalize its roster of shareholders who are eligible for dividend payment. Register with us now for your free membership at: Today, AWS is promoting its ex-dividend coverage on JNJ. Get our free coverage by signing up to: On April 27, 2017, Johnson & Johnson announced that its Board of Directors has declared a 5.0% increase in the quarterly dividend rate from $0.80 per share to $0.84 per share. The next quarterly dividend is payable on June 13, 2017, to shareholders of record as of the close of business on May 30, 2017. The ex-dividend date is May 25, 2017. Johnson & Johnson is among the Dividend Aristocrats, the Companies which have raised their annual dividends for at least 25 consecutive years. "In recognition of our 2016 results, strong financial position and confidence in the future of Johnson & Johnson, the Board has voted to increase the quarterly dividend for the 55th consecutive year," said Alex Gorsky, Chairman and CEO of the company. At the new rate, Johnson & Johnson's indicated dividend on an annual basis is $3.36 per share compared to the previous rate of $3.20 per share. This represents a dividend yield of 2.64% against the average dividend yield for the Healthcare sector of 0.80% Johnson & Johnson has a dividend pay-out ratio of 47.3% meaning the Company distributes $0.473 for every $1 earned. Analysts expect Johnson & Johnson to report earnings of $21.39 in the coming year, which means the Company should continue to be able to cover its $3.36 annual dividend. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey. The Company together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. On May 17, 2017, Biosense Webster, Inc., part of the Johnson & Johnson Medical Devices Companies, announced clinical trial results from a first-in-human study evaluating the acute feasibility of an investigational radiofrequency (RF) balloon catheter in treating patients with atrial fibrillation, or Afib. The PV Isolation with a Novel Multi-electrode Radiofrequency Balloon Catheter that allows Directionally-Tailored Energy Delivery (RADIANCE) study was a multicenter, single-arm, first-in-human feasibility study conducted between December 02, 2016, and March 08, 2017, in Europe. The study showed the RF balloon catheter could deliver directionally-tailored energy using multiple electrodes for efficient acute PVI in patients with paroxysmal atrial fibrillation. At the close of trading session on Tuesday, May 23, 2017, Johnson & Johnson's stock price was marginally up by 0.20% to end the day at $127.52. A total volume of 3.97 million shares were exchanged during the session. The Company's share price has surged 13.69% in the past twelve months and 10.68% on YTD basis. The Company's shares are trading at a PE ratio of 21.44 and have a dividend yield of 2.63%. Additionally, the stock currently has a market cap of $343.44 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
News Article | May 8, 2017
-- After a hugely successful PVI-17 trade show in Mumbai, AIPMA is now gearing up for Plastivision India 2019. To mark the official kick-off, AIPMA along with CIPET (Central Institute of Plastics Engineering & Technology) is organizing a launch function of Plastivision 2019 at Le Meridian, New Delhi on Thursday 9May at 7.00 pm.The event will be presided over by the chief guest – Shri Anant Kumar (Hon'ble Minister for Chemicals and Fertilizers & Parliamentary Affairs) while Shri Anuj Kumar Bishnoi (Secretary, Chemicals & Petrochemicals, Govt. of India) and Shri Mansukh L. Mandaviya (Hon'ble MoS for Chemicals and Fertilizers, Shipping, Road Transport & Highways, GoI) will be the guests of honor. Other dignitaries on the list are – Mr. Haren Sanghvi (President, AIPMA), Mr. Ajay Desai (Chairman, PVI 2019), Mr. Kailash B. Murarka (Chairman, National Advisory Board) and Prof. (Dr.) S K Nayak (Chief Patron, PVI 2019).Plastivision India has become the largest plastic industry trade show in India. The PVI-2017, held in January at Mumbai was a resounding success with record-breaking participation (200,000 visitors and 1395+ exhibitors) and business deals being signed up at the five-day event.The show gave impetus to the 'Make in India' program as it displayed a host of special initiatives such as – Job & Career fair, MSME clinic, technical seminars, solar solutions, and lots more! Exhibitors and attendees thanked and praised the organizers of PVI for giving them an opportunity to showcase their offerings and connect with the potential audience.With each edition of the show, PVI continues to see participation of new and returning exhibitors and visitors. According to the organizers, PVI 2019 will build on the positive results established in PVI-2019 and spotlight latest in trends, technologies, products, solutions and exceptional networking events and conferences.It will serve as a mutually beneficial platform for exhibitors and visitors to tap opportunities, share knowledge, meet entrepreneurs from different countries, network and exchange relevant information and meet decision-makers.Slated on 28th February – 4th March 2019 at a new venue, Pragati Maidan, New Delhi, the 11th edition of Plastivision India promises once more to be "beyond expectations"Plastivision India is the major plastic industry event held in India once every three years. Organized by All India Plastic Manufacturer's Association (AIPMA), the largest non-profit apex body that works towards the welfare of plastic fraternity, PVI has a glorious history of 30 years and has journeyed to become the top 10 plastic industry events globally.Visit http://www.plastivision.org for more information.
Hammar A.,PVI Inc |
Venet P.,University Claude Bernard Lyon 1 |
Lallemand R.,INRETS |
Coquery G.,INRETS |
Rojat G.,University Claude Bernard Lyon 1
IEEE Transactions on Industrial Electronics | Year: 2010
One important part of the electrical transportation systems is the energy-storage system. This can be based, for example, on supercapacitors. In this paper, we propose to study its behavior under constraints similar to their uses in power and railway-traction systems. We define an adequate measurement protocol for accelerated aging which is applied to supercapacitors according to two accelerated factors: effective current and temperature. We model the supercapacitors for different states of health. The modeling gives a good estimation of the variation of electrical parameters of the supercapacitor at different states. We reveal general indicators of the supercapacitor's aging, and we discuss about its life cycle. © 2010 IEEE.
PVI Inc | Date: 2013-11-12